Daan Biotherapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$21.3M
- Investors
-
16
Daan Biotherapeutics General Information
Description
Operator of an integrated immune-oncology drug research firm intended to find various treatment strategies and offer new lung cancer drugs. The company uses anticancer immune cell therapy using Natural Killer cells and T cell receptors, and clinical trials based on an independent research infrastructure, enabling healthcare providers with cell therapies, antibodies, and small molecule inhibitors to treat cancer patients.
Contact Information
Website
www.daanbiotpx.comCorporate Office
- 3th Floor, 366, Hangang-daero
- Yongsan-gu
- Seoul, 04323
- South Korea
Corporate Office
- 3th Floor, 366, Hangang-daero
- Yongsan-gu
- Seoul, 04323
- South Korea
Daan Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 25-Jan-2024 | $21.3M | Completed | Generating Revenue | ||
| 1. Seed Round | 28-Mar-2022 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Daan Biotherapeutics Patents
Daan Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026192355-A1 | Novel serum albumin-binding single domain antibody | Pending | 10-Mar-2025 | ||
| WO-2026019161-A1 | Novel anti-ceacam5 antibody and therapeutic agent use thereof | Pending | 19-Jul-2024 | ||
| JP-2026536668-A | Anti-ceacam5 antibody and its uses | Pending | 09-Nov-2023 | ||
| AU-2024375661-A1 | Anti-ceacam5 antibody and use thereof | Pending | 09-Nov-2023 | ||
| EP-4806921-A1 | Anti-ceacam5 antibody and use thereof | Pending | 09-Nov-2023 | A61K39/00 |
Daan Biotherapeutics Signals
Daan Biotherapeutics Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atinum Investment | Venture Capital | Minority | ||
| DAYLI Partners | Venture Capital | Minority | ||
| FuturePlay | Venture Capital | Minority | ||
| Heungkuk Securities | Corporation | Minority | ||
| KB Investment | Venture Capital | Minority |
Daan Biotherapeutics FAQs
-
When was Daan Biotherapeutics founded?
Daan Biotherapeutics was founded in 2020.
-
Where is Daan Biotherapeutics headquartered?
Daan Biotherapeutics is headquartered in Seoul, South Korea.
-
What is the size of Daan Biotherapeutics?
Daan Biotherapeutics has 6 total employees.
-
What industry is Daan Biotherapeutics in?
Daan Biotherapeutics’s primary industry is Drug Discovery.
-
Is Daan Biotherapeutics a private or public company?
Daan Biotherapeutics is a Private company.
-
What is Daan Biotherapeutics’s current revenue?
The current revenue for Daan Biotherapeutics is .
-
How much funding has Daan Biotherapeutics raised over time?
Daan Biotherapeutics has raised $25.4M.
-
Who are Daan Biotherapeutics’s investors?
Atinum Investment, DAYLI Partners, FuturePlay, Heungkuk Securities, and KB Investment are 5 of 16 investors who have invested in Daan Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process